title: [Metastatic breast cancer: is global survival increase a realistic endpoint in phase III clinical trials? Studies on taxanes; studies on trastuzumab].
authors.affiliation: Dipartimento di Oncologia Medica, IRE, Istituto Nazionale Tumori, Regina Elena, Roma.
authors.forename: Emilio
authors.initials: E
authors.lastname: Bria
authors.forename: Barbara
authors.initials: B
authors.lastname: Vanni
authors.forename: Federica
authors.initials: F
authors.lastname: Cuppone
authors.forename: Francesca
authors.initials: F
authors.lastname: Calabretta
authors.forename: Carla
authors.initials: C
authors.lastname: Campanella
authors.forename: Angela
authors.initials: A
authors.lastname: Torsello
authors.forename: Edmondo
authors.initials: E
authors.lastname: Terzoli
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D017326:Clinical Trials, Phase III as Topic / Q000379:methods*; D003131:Combined Modality Therapy; D023381:Endpoint Determination; D005260:Female; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D043823:Taxoids / Q000627:therapeutic use*; D000068878:Trastuzumab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D043823:Taxoids; D000068878:Trastuzumab